Amarantus BioScience Holdings is a biopharmaceutical company centered on the development of diagnostics and therapeutics for the treatment of Alzheimer’s, Parkinson’s and ophthalmological disorders. AMBS’s diagnostic development projects include the lymphocyte proliferation (LymPro) test, a diagnostic blood test for Alzheimer’s, and MSPrecise, a proprietary DNA sequencing assay for the identification of patients with relapsing-remitting multiple sclerosis at first clinical presentation. The company was founded in 2008 and is located in San Francisco, California. For more information, visit the company’s website at www.amarantus.com